Clinical Trials
Category Added in a WPeMatico Campaign
-
Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes
Patients with end-stage kidney disease (ESKD) receiving maintenance dialysis have a high burden of heart failure (HF), with cardiovascular disease the leading cause of death, yet are largely excluded from randomized trials. Using the TriNetX federated electronic health record network, we emulate a target trial comparing initiation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus dipeptidyl…
-
Digital recruitment and prevalence of screen-detected atrial fibrillation in nationwide patch-based ECG screening: the NORSCREEN randomized clinical trial
CONCLUSION: The NORSCREEN trial demonstrates that fully digital, large-scale, site-less AF screening is feasible and effective in an at-risk population, identifying previously undiagnosed AF in 1.9% of screened individuals and showing high adherence to therapeutic recommendations.
-
Population reach and participation rate in opportunistic vs. systematic atrial fibrillation screening: STROKESTOP III
CONCLUSION: Opportunistic screening increased participation among invited individuals and identified a higher-risk population, but its overall population reach was limited by incomplete eligibility assessment. Combining opportunistic and systematic strategies may optimize reach and participation in AF screening programmes.
-
Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, nonrandomized clinical trial
CONCLUSION: FVIII administered at a target dose of 30 IU/kg (allowable range, 25-35 IU/kg) improved global coagulation parameters and achieved effective hemostasis without thrombotic complications, warranting evaluation as part of emicizumab prophylaxis.
-
Safety and Efficacy of Remimazolam Combined with Esketamine for Anesthesia in Elderly Patients Undergoing ERCP: A Randomized Controlled Trial
CONCLUSION: In this selected population of older patients undergoing ERCP, the remimazolam-esketamine regimen was associated with fewer composite SRAEs than propofol-fentanyl while achieving a similar anesthetic regimen success rate. Induction was modestly longer. Tachycardia, hypertension, and psychotomimetic symptoms were numerically more frequent with RE, but event counts were small and estimates were imprecise. Multicenter studies…
-
Process evaluation of the randomized trial-«Care management for older people with cognitive impairment during and after hospitalisation in Germany (intersec-CM)»
CONCLUSIONS: The present process evaluation underlines the necessity and meaningfulness of process evaluations to understand the functionality and procedural feasibility of an RCT. Through the study, significant insights into the «black box» of the implementation of the iCM intervention could be gained.
-
Effects of 660 nm & 808 nm photo-biomodulation on S100A8/A9 in symptomatic pulpitis: a randomized controlled trial
Photobiomodulation (PBM) modulates inflammation and promotes tissue repair. S100A8/A9 is a neutrophil-derived calcium-binding heterodimer that acts as a pro‑inflammatory damage‑associated molecular pattern, serving as a biomarker of inflammation. This study aimed to evaluate the effects of PBM at 660 nm and 808 nm wavelengths on S100A8/A9 levels in pulp blood (PB) and gingival crevicular fluid…
-
Effects of reduced gluten intake through the inclusion of yellow pea-based products on abdominal symptoms in habitual wheat consumers: a non-randomized clinical trial
CONCLUSIONS: Yellow pea-based products (YPP, YPB, and YPC) may represent a promising dietary strategy for alleviating abdominal symptoms in individuals with high wheat consumption. This study was registered in the UMIN Clinical Trials Registry (UMIN Trial ID: UMIN000056466).
-
Tamsulosin versus tamsulosin plus tolterodine for the treatment of distal ureteral stones
CONCLUSION: The combination of tamsulosin and tolterodine demonstrated superior efficacy in terms of stone expulsion rate and reduced expulsion time for distal ureteral stones compared to tamsulosin monotherapy. This combination therapy may offer a more effective medical expulsive therapy option for patients with distal ureteral calculi.
-
A distinct serum metabolic profile characterizes osteosarcopenia: identifying potential metabolic biomarkers
CONCLUSIONS: Osteosarcopenia was associated with a multi-pathway serum metabolic signature that differed from osteoporosis alone, supporting the possibility that osteosarcopenia represents an integrated musculoskeletal phenotype rather than merely the additive coexistence of muscle and bone loss. The identified metabolites provide preliminary mechanistic insight and discovery-level biomarker candidates, but they require targeted quantitative validation and external…